MORRISVILLE – Novan, a developer of dermatology treatments, has landed an amended licensing agreement with a Japanese firm that is worth an $11 million upfront payment and milestone payments as well as royalties.
The deal had been announced in 2017 and has been expanded to include an additional Novan product.
Satao Pharmaceutical secured licensing and commercialization projects for Novan’s SB204, a treatment for acne, and SB206, which targets viral skin infections.
The $11 million will be paid over 12 months.
“We are pleased to announce this expanded partnership with Sato to now include SB206,” said Novan President Nathan Stasko, who also serves as chief scientific officer. “Japan is the second largest dermatology market in the world where skin diseases such as acne, molluscum and warts have substantial prevalences. Continued interest from a closely aligned and strong partner like Sato further reinforces the science behind our nitric oxide platform and its translation into a broad array of dermatological disorders.”
